Charles Schwab Investment Management Inc Unity Biotechnology, Inc. Transaction History

Charles Schwab Investment Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.29 $25,732 - $59,276	45,951 New	45,951 $26,000
Q1 2022 May 13, 2022	SELL	$0.72 - $1.86 $9,067 - $23,424	-12,594 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$2.91 - $4.5 $381,160 - $589,423	-130,983 Reduced 91.23%	12,594 $38,000
Q2 2021 Aug 16, 2021	SELL	$4.15 - $6.3 $343,723 - $521,797	-82,825 Reduced 36.58%	143,577 $667,000
Q1 2021 May 17, 2021	BUY	$5.51 - $9.42 $40,972 - $70,047	7,436 Added 3.4%	226,402 $1.36 Million
Q4 2020 Feb 16, 2021	BUY	$3.42 - $6.36 $31,409 - $58,410	9,184 Added 4.38%	218,966 $1.15 Million
Q3 2020 Nov 13, 2020	BUY	$2.94 - $12.43 $62,983 - $266,287	21,423 Added 11.37%	209,782 $726,000
Q2 2020 Aug 14, 2020	BUY	$5.28 - $9.67 $110,589 - $202,538	20,945 Added 12.51%	188,359 $1.64 Million
Q1 2020 May 15, 2020	BUY	$5.0 - $7.6 $50,055 - $76,083	10,011 Added 6.36%	167,414 $972,000
Q4 2019 Feb 07, 2020	BUY	$5.99 - $8.38 $41,336 - $57,830	6,901 Added 4.59%	157,403 $1.14 Million
Q3 2019 Nov 08, 2019	BUY	$5.62 - $9.63 $458,136 - $785,027	81,519 Added 118.17%	150,502 $919,000
Q2 2019 Aug 09, 2019	BUY	$7.59 - $10.21 $56,644 - $76,197	7,463 Added 12.13%	68,983 $656,000
Q1 2019 May 14, 2019	BUY	$7.65 - $16.66 $3,021 - $6,580	395 Added 0.65%	61,520 $499,000
Q4 2018 Feb 14, 2019	BUY	$10.76 - $17.25 $413,184 - $662,400	38,400 Added 168.98%	61,125 $994,000
Q3 2018 Nov 13, 2018	BUY	$14.34 - $22.97 $32,193 - $51,567	2,245 Added 10.96%	22,725 $371,000
Q2 2018 Aug 08, 2018	BUY	$12.76 - $16.94 $261,324 - $346,931	20,480 New	20,480 $309,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.